Shinge Shafiu A Umar, Zhang Binbin, Zheng Baixin, Qiang Yongjia, Ali Hussein M, Melchiade Youmbi T Vanessa, Zhang Lu, Gao Minnan, Feng Guibin, Zeng Kuan, Yang Yanqi
Department of Cardiovascular Surgery, The Eighth Affiliated Hospital of Sun Yat-sen University, Futian, Shenzhen, 518033, China.
Department of Pediatric, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
J Epidemiol Glob Health. 2025 Aug 22;15(1):108. doi: 10.1007/s44197-025-00455-1.
Culture-negative infective endocarditis (CNE) remains a significant diagnostic challenge in cardiology and infectious disease, often leading to delayed or empirical treatment. Metagenomic next-generation sequencing (mNGS) has emerged as a complementary diagnostic tool capable of identifying fastidious, unexpected, or novel pathogens without prior assumptions. This narrative review synthesizes evidence from 152 studies (2015-2024), evaluating mNGS within existing diagnostic frameworks for culture-negative IE. Compared to conventional diagnostics (blood cultures, PCR, 16 S rRNA sequencing), mNGS demonstrates enhanced detection capabilities for polymicrobial infections and rare pathogens, though methodological heterogeneity across studies precludes definitive performance comparisons. Performance varies substantially based on sample type, sequencing platform, and bioinformatic pipelines. Real-world applications reveal persistent challenges, including cost barriers, interpretive complexities in low-biomass samples, and contamination risks. Integration with host-response biomarkers and AI-driven interpretation platforms shows promise for advancing clinical utility. For mNGS to be effectively integrated into routine CNE care, standardization, regulatory clarity, and equitable implementation will be essential.
血培养阴性感染性心内膜炎(CNE)在心脏病学和传染病领域仍然是一项重大的诊断挑战,常常导致治疗延迟或经验性治疗。宏基因组下一代测序(mNGS)已成为一种辅助诊断工具,能够在无需预先假设的情况下识别苛养菌、意外病原体或新病原体。这篇叙述性综述综合了152项研究(2015 - 2024年)的证据,在血培养阴性感染性心内膜炎的现有诊断框架内评估mNGS。与传统诊断方法(血培养、PCR、16S rRNA测序)相比,mNGS对混合感染和罕见病原体具有更强的检测能力,不过各研究之间的方法学异质性使得无法进行明确的性能比较。性能因样本类型、测序平台和生物信息学流程而异。实际应用中仍存在持续挑战,包括成本障碍、低生物量样本的解读复杂性以及污染风险。与宿主反应生物标志物和人工智能驱动的解读平台相结合有望提高临床实用性。为使mNGS有效融入CNE常规诊疗,标准化、监管明确性和公平实施至关重要。